Cyberonics Announces 1,100th Patient Treated With VNS Therapy(tm) for Treatment-Resistant Depression (TRD) Since FDA (Boursorama)
HOUSTON, May 1 /PRNewswire-FirstCall/ -- Cyberonics, Inc. today announced that the 1,100th patient in the U.S. has been treated with Vagus Nerve Stimulation (VNS) Therapy for treatment-resistant depression (TRD) since FDA approval in July 2005. VNS Therapy is the first FDA-approved treatment option developed, studied, approved and labeled specifically for patients with TRD.

One Midsize Company's Answer To Compliance Pain (Government Enterprise)
Compliance with governmentregulations can be a big cost and productivity drain on small and midsize businesses. Care Rehab has found that automated inventory tracking can remove much of the pain.

Management Control Key to QSR Compliance (Medical Device Link)
Strong management control is central in establishing an organized quality system. A manager with executive responsibility has the ultimate responsibility to set up and change a company s procedures to comply with the quality system regulation (QSR) requirements.